Immunogenicity, effectiveness and safety of combined hepatitis A and B vaccine: a systematic literature review

References

• World Health Organization. Hepatitis A - Fact sheet #328 [Internet]. World Health Organization. Updated July 2015. [cited 2016 Jan 14]. Available from: http://www.who.int/mediacentre/factsheets/fs328/en/
   Google Scholar
• World Health Organization. Hepatitis B - Fact sheet #204 [Internet]. World Health Organization. Updated July 2015. [cited 2016 Jan 14]. Available from: http://www.who.int/mediacentre/factsheets/fs204/en/
   Google Scholar
• Beran J. Bivalent inactivated hepatitis A and recombinant hepatitis B vaccine. Expert Rev Vaccines. 2007;6(6):891–902.
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO position paper on hepatitis A vaccines - June 2012. Weekly Epidemiological Record. 2012;28-29(87):261–276.
   Google Scholar
• Burroughs AK, Westaby D. Chapter 7 - Liver, biliary tract and pancreatic disease. In: Kumar P, Clark M, editors. Clinical medicine. 6th ed. London: Elsevier Saunders; 2005. p. 362–364.
   Google Scholar
• World Health Organization. WHO position paper - hepatitis B vaccines. Weekly Epidemiological Record. 2009;40(84):405–420.
   Google Scholar
• Hendrickx G, Vorsters A, Van Damme P. Advances in hepatitis immunization (A, B, E): public health policy and novel vaccine delivery. Curr Opin Infect Dis. 2012;25(5):578–583.
   PubMed Web of Science ®Google Scholar
• Ott JJ, Irving G, Wiersma ST. Long-term protective effects of hepatitis A vaccines. A systematic review. Vaccine. 2012;31(1):3–11.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Immunization coverage - Fact sheet #378 [Internet]. World Health Organization. Updated September 2015. [cited 2016 Jan 14]. Available from: http://www.who.int/mediacentre/factsheets/fs378/en/
   Google Scholar
• Marshall H, Nolan T, Diez Domingo J, et al Long-term (5-year) antibody persistence following two- and three-dose regimens of a combined hepatitis A and B vaccine in children aged 1-11 years. Vaccine. 2010;28(27):4411–4415.
   PubMed Web of Science ®Google Scholar
• Thoelen S, Van Damme P, Leentvaar-Kuypers A, et al. The first combined vaccine against hepatitis A and B: an overview. Vaccine. 1999;17(13–14):1657–1662.
   PubMed Web of Science ®Google Scholar
• Kallinowski B, Jilg W, Buchholz L, et al. Immunogenicity of an accelerated vaccination regime with a combined hepatitis a/b vaccine in patients with chronic hepatitis C. Z Gastroenterol. 2003;41(10):983–990.
   PubMed Web of Science ®Google Scholar
• Henkle E, Lu M, Rupp LB, et al. Hepatitis A and B immunity and vaccination in chronic hepatitis B and C patients in a large United States cohort. Clin Infect Dis. 2015;60(4):514–522.
   PubMed Web of Science ®Google Scholar
• Van Damme P, Leroux-Roels G, Crasta P, et al. Antibody persistence and immune memory in adults, 15 years after a three-dose schedule of a combined hepatitis A and B vaccine. J Med Virol. 2012;84(1):11–17.
   PubMed Web of Science ®Google Scholar
• Beran J, Kervyn D, Wertzova V, et al. Comparison of long-term (10 years) immunogenicity of two- and three-dose regimens of a combined hepatitis A and B vaccine in adolescents. Vaccine. 2010;28(37):5993–5997.
   PubMed Web of Science ®Google Scholar
• Flynn PM, Cunningham CK, Rudy B, et al. Hepatitis B vaccination in HIV-infected youth: a randomized trial of three regimens. J Acquir Immune Defic Syndr. 2011;56(4):325–332.
   PubMed Web of Science ®Google Scholar
• Spradling PR, Kamili S, Xing J, et al. Response to challenge dose among young adults vaccinated for hepatitis B as infants: importance of detectable residual antibody to hepatitis B surface antigen. Infect Control Hosp Epidemiol. 2015;36(5):529–533.
   PubMed Web of Science ®Google Scholar
• Ambrosch F, Wiedermann G, André FE, et al. Clinical and immunological investigation of a new combined hepatitis A and hepatitis B vaccine. J Med Virol. 1994;44(4):452–456.
   PubMed Web of Science ®Google Scholar
• Bruguera M, Bayas JM, Vilella A, et al. Immunogenicity and reactogenicity of a combined hepatitis A and B vaccine in young adults. Vaccine. 1996;14(15):1407–1411.
   PubMed Web of Science ®Google Scholar
• Czeschinski PA, Binding N, Witting U. Hepatitis A and hepatitis B vaccinations: immunogenicity of combined vaccine and of simultaneously or separately applied single vaccines. Vaccine. 2000;18(11–12):1074–1080.
   PubMed Web of Science ®Google Scholar
• De Schryver A, Verstrepen K, Vandersmissen L, et al Comparative immunogenicity of two vaccination schedules of a combined hepatitis A and B vaccine in healthy volunteers. J Viral Hepat. 2011;18(4):e5–10.
   PubMed Web of Science ®Google Scholar
• Höhler T, Groeger-Bicanic G, Hoet B, et al. Antibody persistence and immune memory elicited by combined hepatitis A and B vaccination in older adults. Vaccine. 2007;25(8):1503–1508.
   PubMed Web of Science ®Google Scholar
• Joines RW, Blatter M, Abraham B, et al. A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix-B) in adults. Vaccine. 2001;19(32): 4710–4719.
   PubMed Web of Science ®Google Scholar
• Kallinowski B, Bock HL, Clemens R, et al. Immunogenicity and reactogenicity of a combined hepatitis A/B candidate vaccine: first results. Liver. 1996;16(4):271–273.
   PubMedGoogle Scholar
• Knöll A, Hottenträger B, Kainz J, et al. Immunogenicity of a combined hepatitis A and B vaccine in healthy young adults. Vaccine. 2000;18(19):2029–2032.
   PubMed Web of Science ®Google Scholar
• Rendi-Wagner P, Kundi M, Stemberger H, et al. Antibody-response to three recombinant hepatitis B vaccines: comparative evaluation of multicenter travel-clinic based experience. Vaccine. 2001;19(15–16):2055–2060.
   PubMed Web of Science ®Google Scholar
• Rieger MA, Hofmann F, Michaelis M. Simultaneous vaccination against hepatitis A and B: results of an open, randomized study from the occupational health point of view. Int J Occup Med Environ Health. 2004;17(3):379–391.
   PubMedGoogle Scholar
• Van Der Wielen M, Van Damme P, Chlibek R, et al. Hepatitis A/B vaccination of adults over 40 years old: comparison of three vaccine regimens and effect of influencing factors. Vaccine. 2006;24(26):5509–5515.
   PubMed Web of Science ®Google Scholar
• Chlibek R, Von Sonnenburg F, Van Damme P, et al. Antibody persistence and immune memory 4 years post-vaccination with combined hepatitis A and B vaccine in adults aged over 40 years. J Travel Med. 2011;18(2):145–148.
   PubMed Web of Science ®Google Scholar
• Van Herck K, Leroux-Roels G, Van Damme P, et al. Ten-year antibody persistence induced by hepatitis A and B vaccine (Twinrix) in adults. Travel Med Infect Dis. 2007;5(3):171–175.
   PubMedGoogle Scholar
• Williams RE, Sena AC, Moorman AC, et al. Hepatitis B vaccination of susceptible elderly residents of long term care facilities during a hepatitis B outbreak. Vaccine. 2012;30(21):3147–3150.
   PubMed Web of Science ®Google Scholar
• Wolters B, Muller T, Ross RS, et al. Comparative evaluation of the immunogenicity of combined hepatitis A and B vaccine by a prospective and retrospective trial. Hum Vaccin. 2009;5(4):248–253.
   PubMed Web of Science ®Google Scholar
• Wolters B, Junge U, Dziuba S, et al. Immunogenicity of combined hepatitis A and B vaccine in elderly persons. Vaccine. 2003;21(25–26):3623–3628.
   PubMed Web of Science ®Google Scholar
• Thompson SC, Norris M. Immunogenicity and reactogenicity of a combined hepatitis A-hepatitis B vaccine in adolescents. Int J Infect Dis. 1998;2(4):193–196.
   PubMedGoogle Scholar
• Connor BA, Blatter MM, Beran J, et al. Rapid and sustained immune response against hepatitis A and B achieved with combined vaccine using an accelerated administration schedule. J Travel Med. 2007;14(1):9–15.
   PubMed Web of Science ®Google Scholar
• Frey S, Dagan R, Ashur Y, et al. Interference of antibody production to hepatitis B surface antigen in a combination hepatitis A/hepatitis B vaccine. J Infect Dis. 1999;180(6):2018–2022.
   PubMed Web of Science ®Google Scholar
• Nothdurft HD, Dietrich M, Zuckerman JN, et al. A new accelerated vaccination schedule for rapid protection against hepatitis A and B. Vaccine. 2002;20(7–8):1157–1162.
   PubMed Web of Science ®Google Scholar
• Levie K, Beran J, Collard F, et al. Long term (24 months) follow-up of a hepatitis A and B vaccine, comparing a two and three dose schedule in adolescents aged 12-15 years. Vaccine. 2002;20(19–20):2579–2584.
   PubMed Web of Science ®Google Scholar
• Ostergaard L, Silfverdal SA, Berglund J, et al. A tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when co-administered with Twinrix((R)) in subjects aged 11-17 years: an open, randomised, controlled trial. Vaccine. 2012;30(4):774–783.
   PubMed Web of Science ®Google Scholar
• Pedersen C, Breindahl M, Aggarwal N, et al. Randomized trial: immunogenicity and safety of coadministered human papillomavirus-16/18 AS04-adjuvanted vaccine and combined hepatitis A and B vaccine in girls. J Adolesc Health. 2012;50(1):38–46.
   PubMed Web of Science ®Google Scholar
• Roberton D, Marshall H, Nolan TM, et al. Reactogenicity and immunogenicity profile of a two-dose combined hepatitis A and B vaccine in 1-11-year-old children. Vaccine. 2005;23(43):5099–5105.
   PubMed Web of Science ®Google Scholar
• Van Damme P, Leroux-Roels G, Law B, et al. Long-term persistence of antibodies induced by vaccination and safety follow-up, with the first combined vaccine against hepatitis A and B in children and adults. J Med Virol. 2001;65(1):6–13.
   PubMed Web of Science ®Google Scholar
• Diaz-Mitoma F, Law B, Subramanya A, et al. Long-term antibody persistence induced by a combined hepatitis A and B vaccine in children and adolescents. Vaccine. 2008;26(14):1759–1763.
   PubMed Web of Science ®Google Scholar
• Duval B, Gilca V, Boulianne N, et al. Immunogenicity of two paediatric doses of monovalent hepatitis B or combined hepatitis A and B vaccine in 8-10-year-old children. Vaccine. 2005;23(31):4082–4087.
   PubMed Web of Science ®Google Scholar
• Gilca V, Dionne M, Boulianne N, et al. Long-term immunogenicity of two pediatric doses of combined hepatitis A and B or monovalent hepatitis B vaccine in 8 to 10-year-old children and the effect of a challenge dose given seven years later. Pediatr Infect Dis J. 2009;28(10):916–918.
   PubMed Web of Science ®Google Scholar
• Belderok SM, Sonder GJ, Van Rossum M, et al. Evaluation of immune responses to combined hepatitis A and B vaccine in HIV-infected children and children on immunosuppressive medication. Vaccine. 2013;31(38):4156–4163.
   PubMed Web of Science ®Google Scholar
• Burgess MA, McIntyre PB, Hellard M, et al. Antibody persistence six years after two doses of combined hepatitis A and B vaccine. Vaccine. 2010;28(10):2222–2226.
   PubMed Web of Science ®Google Scholar
• Burgess MA, Rodger AJ, Waite SA, et al. Comparative immunogenicity and safety of two dosing schedules of a combined hepatitis A and B vaccine in healthy adolescent volunteers: an open, randomised study. Vaccine. 2001;19(32):4835–4841.
   PubMed Web of Science ®Google Scholar
• Cunningham CK, Rudy BJ, Xu J, et al. Randomized trial to determine safety and immunogenicity of two strategies for hepatitis B vaccination in healthy urban adolescents in the United States. Pediatr Infect Dis J. 2010;29(6):530–534.
   PubMed Web of Science ®Google Scholar
• Lee SD, Chan CY, Yu MI, et al. A two dose combined hepatitis A and B vaccine in Chinese youngsters. J Med Virol. 1999;59(1):1–4.
   PubMed Web of Science ®Google Scholar
• Ramonet M, Da Silveira TR, Lisker-Melman M, et al. A two-dose combined vaccine against hepatitis A and hepatitis B in healthy children and adolescents compared to the corresponding monovalent vaccines. Arch Med Res. 2002;33(1):67–73.
   PubMed Web of Science ®Google Scholar
• Usonis V, Meriste S, Bakasenas V, et al. Immunogenicity and safety of a combined hepatitis A and B vaccine administered concomitantly with either a measles-mumps-rubella or a diphtheria-tetanus-acellular pertussis-inactivated poliomyelitis vaccine mixed with a Haemophilus influenzae type b conjugate vaccine in infants aged 12-18 months. Vaccine. 2005;23(20):2602–2606.
   PubMed Web of Science ®Google Scholar
• Van Damme P, Kafeja F, Van Der Wielen M, et al. Long-term immunogenicity and immune memory after two doses of the adult formulation of a combined hepatitis A and B vaccine in children 1 to 11 years of age. Pediatr Infect Dis J. 2011;30(8):703–705.
   PubMed Web of Science ®Google Scholar
• Van Der Wielen M, Van Damme P, Collard F. A two dose schedule for combined hepatitis A and hepatitis B vaccination in children ages one to eleven years. Pediatr Infect Dis J. 2000;19(9):848–853.
   PubMed Web of Science ®Google Scholar
• Domínguez A, Oviedo M, Carmona G, et al. Epidemiology of hepatitis A before and after the introduction of a universal vaccination programme in Catalonia, Spain. J Viral Hepat. 2008;15(Suppl 2):51–56.
   PubMed Web of Science ®Google Scholar
• Vilella A, Dal-Ré R, Simó D, et al. Reactogenicity profile of a combined hepatitis A and B vaccine in clinical practice: a naturalistic study in adult travellers. Vaccine. 2005;23(19):2465–2469.
   PubMed Web of Science ®Google Scholar
• Woo EJ, Miller NB, Ball R. Adverse events after hepatitis A B combination vaccine. Vaccine. 2006;24(14):2685–2691.
   PubMed Web of Science ®Google Scholar
• Moro PL, Museru OI, Niu M, et al. Reports to the Vaccine Adverse Event Reporting System after hepatitis A and hepatitis AB vaccines in pregnant women. Am J Obstet Gynecol. 2014;210(6):561.e1–561.e6.
   PubMed Web of Science ®Google Scholar
• Thudi K, Yadav D, Sweeney K, et al. Physicians infrequently adhere to hepatitis vaccination guidelines for chronic liver disease. PLoS One. 2013;8(7):e71124.
   PubMed Web of Science ®Google Scholar
• Van Damme P, Chlibek R, Keeffe E. Hepatitis A and B vaccination in elderly travellers. European Gastroenterology & Hepatology Review. 2011;7(2):84–92.
   Google Scholar
• Guess HA. Combination vaccines: issues in evaluation of effectiveness and safety. Epidemiologic Reviews. 1999;21(1):89–95.
   PubMed Web of Science ®Google Scholar
• Levine H, Kopel E, Anis E, et al. The impact of a national routine immunisation programme initiated in 1999 on hepatitis A incidence in Israel, 1993 to 2012. Euro Surveill. 2015;20(7):3–10.
   PubMedGoogle Scholar
• Chiang CJ, Yang YW, You SL, et al. Thirty-year outcomes of the national hepatitis B immunization program in Taiwan. JAMA. 2013;310(9):974–976.
   PubMed Web of Science ®Google Scholar